This, together with the pathogenetic involvement of IL-12 and IL-13, provides the mechanistic bases for clinical research of Tyk2 inhibitors in the treatment of bowel inflammatory diseases [38,43,44]. This evidence concerns the gene TYK2 and inflammatory bowel disease.